Podcasts about wales hospital

This special episode's participants are Winston Fung, Clinical Assistant Professor/ Associate Consultant, Division of Nephrology at the Prince of Wales Hospital, The Chinese University of Hong Kong; Isabelle Ethier, Nephrologist, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Canada and Caroline Stigant, Assistant Professor of Medicine, Division of Nephrology, University of British Columbia. This is the  first of a multi-part ELP-GreenK series and part one we discuss the environmental impact of kidney care and what we can do about it! This episode is also part of the larger ISN GREEN-K initiative – Global Environmental Evolution in Nephrology and Kidney Care Curriculum on the ISN Academy. Visit to delve deeper into environmentally sustainable kidney care, all in the name of caring for our patients and the environment!

In this piece we discuss blood management in emergency and elective surgery with Matthew Wiles, an anaesthetist from Sheffield, UK, and editor of the journal Anaesthesia, and Catherine Downs, an anaesthetist from Sydney, Australia. The episode delves into haemorrhage associated with trauma and major surgery, and the benefits of point of care testing. We also took the opportunity to discuss authorship of scholarly work and the need to support emerging researchers and site collaborators. Presented by Andy Cumpstey and Kate Leslie on location at the Annual Scientific Meeting of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine in Cairns, Australia, with their guests, Dr Matthew Wiles, Consultant Anaesthetist and Clinical Lead for Major Trauma, Sheffield Hospitals NHS Foundation Trust, and Honorary Senior Clinical Lecturer, Sheffield University, Sheffield, UK, and Dr Catherine Downs, Consultant Anaesthetist, Prince of Wales Hospital, and Senior Lecturer, Randwick Clinical Campus, University of New South Wales, Sydney, Australia

A listener has raised the alarm after discovering a second antisemitic sticker at the same location in Prince of Wales Hospital, just two months after first reporting similar incidents.See omnystudio.com/listener for privacy information.

In this episode of the Mind Movement Health Podcast, host Kate Boyle is joined by Associate Professor Sanjay Warrier, a leading breast cancer surgeon, to discuss crucial topics surrounding breast cancer. The conversation covers essential aspects of breast cancer prevention, lifestyle choices, and advanced treatment options. Sanjay Warrier provides insights into the rising prevalence of breast cancer and emphasizes the importance of regular breast checks, while also breaking down different types of breast cancer and their respective interventions. The discussion delves into genetic, lifestyle, and environmental factors that influence risk and explores the latest advancements in breast cancer treatments aimed at improving patient outcomes. Kate and her guest also highlight the significance of diet, exercise, and mindfulness in supporting overall health and reducing cancer risk. With a focus on education and proactive health management, this episode is a must-listen for anyone seeking to deepen their understanding of breast cancer and learn practical strategies for prevention.   Connect with Associate Professor Sanjay Warrier: Associate Professor Sanjay Warrier is a Sydney-based breast surgeon at Chris O'Brien Lifehouse, Royal Prince Alfred Hospital, and the Mater Hospital. After completing his surgical training at Prince of Wales Hospital, Dr. Warrier pursued advanced research in Breast Surgical Oncology and Oncoplastic Surgery at the Sydney Royal Hospital for Women and Royal Prince Alfred Hospital. Currently, Associate Professor Warrier serves as the Chairman of Breast Training for Australia and New Zealand and is a member of the Executive Council for Breastsurganz. He is also the designated surgical lead for BreastScreen Central Sydney. Associate Professor Warrier has a keen interest in innovation within breast reconstruction, becoming the first user of Spy technology in Australia and a pioneer in robotic mastectomies in the Southern Hemisphere. In 2013, Dr. Warrier received the Patron's Prize for the best scientific research presentation at Royal Prince Alfred Hospital. His Master's thesis focused on a novel biomarker that predicts poor outcomes in breast cancer.  

A 2GB listener has pointed out to Clinton Maynard that he has seen pro-Palestine stickers and messaging on hospital grounds at Prince of Wales Hospital in Randwick.See omnystudio.com/listener for privacy information.

When Louisa Hope walked into Sydney’s Lindt Cafe 5 years ago she didn't expect her life would change forever. Louisa is one of the Sydney Siege survivors. She and her mother were held at gunpoint and trapped for 17 hours before the gunman executed cafe manager Tori Johnston on his knees in front of her. Another hostage, Katrina Dawson was killed moments later in gunfire when police stormed the cafe. Louisa joins Mia Freedman to talk through what happened that day and how she feels five years on. Towards the end of the siege, Louisa was shot in the foot and went to The Prince of Wales Hospital where she spent 3 months as a patient. Follow No Filter CREDITS: Host: Mia Freedman With thanks to Louisa Hope Producer: Bridget Northeast THE END BITS Support independent women's media Check out The Quicky Instagram here Feeling festive? Gift a Mamamia subscription! Head here to give the best stuff for women. Liked this episode? Listen to these: GET IN TOUCH Share your story, feedback, or dilemma! Send us a voice note or email us at thequicky@mamamia.com.auBecome a Mamamia subscriber: https://www.mamamia.com.au/subscribeSee omnystudio.com/listener for privacy information.

In a Phase I study with 318 patients in China and Australia the antibody-drug conjugate (ADC) IBI354 was found to be safe and have promising efficacy in patients whose breast and other solid tumors tested positive for HER2 or were categorized as “HER2-low.” At ESMO Congress 2024, the study also reported a low rate of interstitial lung disease in patients treated with the ADC. Oncology Times correspondent Peter Goodwin talked with Christina Teng, PhD, the presenting author of the new research from Scientia Clinical Research and the Prince of Wales Hospital in Sydney, Australia.

Creo Medical Group CEO Craig Gulliford joined Proactive's Stephen Gunnion following the deployment of the Speedboat UltraSlim device in the Asia Pacific region, marking a significant milestone for the company. The Speedboat UltraSlim, a culmination of years of development, miniaturizes laparoscopic advanced energy capabilities into a compact device enhancing endoscopic surgery. This innovation enables precise surgical procedures with minimal invasiveness, targeting precancerous and cancerous lesions in the gastrointestinal tract. Gulliford highlighted the device's successful clinical applications in various regions, including the US, South America, Europe, and recently at the Prince of Wales Hospital in Hong Kong, focusing on stomach and colon lesions. The technology aims to reduce the need for conventional surgery, offering a safer alternative with lower complication rates. Additionally, Creo announced a strategic collaboration with Khalifa University of Science and Technology in Abu Dhabi to develop intellectual property and expand its technological reach into the Middle East. This partnership aims to foster innovation and enhance medical outcomes, reinforcing Creo Medical's commitment to advancing medical technology and improving patient care globally. ‌ #CreoMedicalGroup #SpeedboatInjectUltra #MedicalInnovation #EndoscopicSurgery #LaparoscopicSurgery #AsiaPacificHealthcare #MedicalDevices #GastrointestinalHealth #PrecancerousLesionsTreatment #HealthcareTechnology #CraigGulliford #MedicalResearch #KhalifaUniversity #MedicalCollaboration #GlobalHealthcare #SurgicalDevices #Endoscopy #MinimallyInvasiveSurgery #MedicalIndustryInterview #ProactiveLondon #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

This piece focuses upon trainee led research as Monty Mythen and Desiree Chappell speak with this year's trainee representative Cameron Dunn, Consultant Anaesthetist at Prince of Wales Hospital and Community Health Services, Sydney. This year TopMedTalk is proud to be providing exclusive coverage of the annual ANZCA conference, the professional body responsible for the specialties of anaesthesia and pain medicine in Australia and New Zealand. For more on ANZCA go here: https://www.anzca.edu.au/ And join in the conversation by checking out their socials here: instagram.com/the_anzca/ https://facebook.com/ANZCA1992 https://youtube.com/AnzcaEduAu

Lentigo maligna – a subtype of in situ melanoma – presents diagnostic and treatment challenges for clinicians. In this podcast, Dr Michael Rtshiladze leads a multidisciplinary discussion to unravel our understanding of the pathology, diagnosis and management of lentigo maligna, including: clinical and histological presentation tools to diagnose and monitor lesions the impact of different types of biopsies the importance of mapping the extent of lesions the challenge of surgical management in cosmetically sensitive areas the role of radiation therapy and topical treatments when to refer your patient. The discussion concludes with a case study to summarise key learnings. This podcast is suitable for Plastic Surgeons, General Surgeons, Dermatologists, Oncologists, Pathologists, GPs, Nurses and other healthcare professionals. SPEAKERS Dr Michael Rtshiladze - Plastic and Reconstructive Surgeon, Melanoma Institute Australia, Royal Prince Alfred Hospital, The Prince of Wales Hospital, St George Hospital and Sydney Children's Hospital Dr Robert Rawson - Pathologist, Melanoma Institute Australia and Royal Prince Alfred Hospital Prof Pascale Guitera - Dermatologist, Melanoma Institute Australia | Director, Sydney Melanoma Diagnostic Centre at Royal Prince Alfred Hospital | Professorial Research Fellow, The University of Sydney Prof Angela Hong - Radiation Oncologist, Melanoma Institute Australia | Clinical Professor, The University of Sydney RESOURCE AND REFERENCE Lentigo Maligna Patient Information Brochure Crouch G, Sinha S, Lo S, Saw RPM, Lee KK, Stretch J, Shannon K, Guitera P, Scolyer RA, Thompson JF & Ch'ng S. Clinical outcomes following surgical treatment of lentigo maligna of the head and neck. Eur J Surg Oncol. 2021 May;47(5):1145-1151. Please note that this podcast was accurate at the time of recording (December 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA's Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.

In this episode of Psych Matters Professor Henry Brodaty explains recent advances in dementia research, diagnosis, treatment, and care. He presented this topic at the RANZCP Congress 2022 in Sydney, Australia and discusses many of the important points made during the presentation.Professor Henry Brodaty is a researcher, clinician, policy advisor and strong advocate for people with dementia and their carers.  At UNSW Sydney, he is Scientia Professor of Ageing and Mental Health and Co-Director of the Centre for Healthy Brain Ageing. He has published extensively, is a senior psychogeriatrician at Prince of Wales Hospital, Sydney. He serves on multiple committees for the NSW and Australian governments and WHO.Links:Forward with Dementia www.forwardwithdementia.auCheBA www.cheba.unsw.edu.auFeedback:If you have a topic suggestion or would like to participate in a future episode of Psych Matters, we'd love to hear from you.Please contact us by email at: psychmatters.feedback@ranzcp.orgDisclaimer:This podcast is provided to you for information purposes only and to provide a broad public understanding of various mental health topics.  The podcast may represent the views of the author and not necessarily the views of The Royal Australian and New Zealand College of Psychiatrists ('RANZCP'). The podcast is not to be relied upon as medical advice, or as a substitute for medical advice, does not establish a doctor-patient relationship and should not be a substitute for individual clinical judgement.  By accessing The RANZCP's podcasts you also agree to the full terms and conditions of the RANZCP's Website. Expert mental health information and finding a psychiatrist in Australian or New Zealand is available on the RANZCP's Your Health In Mind Website.

Neuroscience of Success.What is Neuroscience? How does it relate to our living successfully?The human body is a fantastic construct designed to be a container that bears life as ordained by God. Its workings are delicate and are seen in the coming together of many functions represented as faculties, each of which meets at a juncture that describes a collaborative relationship. One of those faculties is the central nervous system (CNS).The central nervous system (CNS) comprises the brain and spinal cord. The three broad functions of the CNS are taking in sensory information, processing information, and sending out motor signals.The CNS receives sensory information from the nervous system and controls the body's responses. The central nervous system primarily receives information from various body areas and coordinates this activity to produce the body's responses. https://www.verywellmind.com/what-is-the-central-nervous-system-2794981#:~:text=The%20central%20nervous%20system%20(CNS)%20is%20comprised%20of%20the%20brain,and%20controls%20the%20body's%20responses.Our success at living purposefully and succeeding is primarily a function of how we manage our central nervous system and optimize its workings.The summary above clearly points to what neuroscience is all about; any or all of the sciences, such as neurochemistry and experimental psychology, which deal with the structure or function of the nervous system and brain.In this episode of the word café, we are so pleased to talk about this and honored to have an award-winning neuroscientist, Niyi Borire, to drive this conversation.Niyi Borire is the Director, Southwest Neurology, Consultant Neurologist, NeuroLeadership Expert, Executive Coach, Trainer, and Keynote SpeakerHe is a neurologist with a subspeciality interest in nerve and muscle disorders such as nerve injury and entrapment, neuropathy, myopathy and neurodegenerative disease. He is actively involved in research that aims to develop novel biomarkers for the early diagnosis and prevention of peripheral nerve disorders. His research has been awarded the 2015 Jim McLeod Young Investigator Award (of the Australian and New Zealand Association of Neurologists Annual), the 2016 Tow Coast Association Research Early Career Awards (from the Prince of Wales Hospital), and the 2017 Golseth Young Investigator Award (presented by the American Association of Neuromuscular and Electrodiagnostic Medicine). Dr. Borire is also a Conjoint Lecturer in medicine at UNSW and is involved with undergraduate and postgraduate teaching. He has published numerous scientific articles and regularly presents at local and international conferences in the field of Neuromuscular and Electrodiagnostic Medicine.Support the show

Clinician burnout is yet to be properly addressed; how can technology help? Dr May Lin Tan is a general practitioner at Bronte Family Doctors and the Burke Street Clinic.  Dr Micah Vincent is an advanced training doctor of general paediatrics at Sydney Children's Hospital Network. Dr Paul Lilburn is an interventional pulmonologist at Prince of Wales Hospital. Dr Travis Bias is 3M's chief medical information officer clinician solutions. 3M Health Information Systems is committed to creating more time to care and leading the shift from volume to value-based care.  In this episode titled “Doctors on drivers of clinical burnout and technology's role as a problem solver,” Travis, May, Micah and Paul discuss clinical burnout and the factors that might divert attention from patient care. They also identify areas where technology may intervene to free up time to care for patients. This episode is based on clinician burnout and how its drivers may potentially be quelled with technology's help. Also, hear about the personal burnout experiences of three doctors as they relate their stories and make suggestions for applicable solutions.  Check out the episode and full show notes here. To see the latest information, news, events and jobs on offer at 3M, visit their Talking HealthTech Directory here.  Keen to take your healthtech to the next level? Become a THT+ Member for access to our online community forum, quarterly summits and more exclusive content.  For more information visit here.

We dedicate this episode to the countless early career medical professionals across the globe who have had to brave the unenviable transition between medical school and the front lines of the COVID-19 pandemic. Join us as we talk to Esther Yewpick Lee Millennium Scholar and Oxford University DPhil Candidate Timothy Tipoe about his experiences during this transformative moment in medical history. Dr Tipoe, or 'Tim', as he is known to his friends, graduated from the Chinese University of Hong Kong in 2019 and was a medical intern when the pandemic began. His actions while working at Prince of Wales Hospital in 2020 are exemplary of the extraordinary courage that has been shown by thousands of early career healthcare workers the world over. Tune in to learn about the impact these last few years have had on new doctors and how many like Tim have found strength in such challenging times. Please have a listen to show your support. Music composed by: Justin Yau Interviewer and podcast co-creator: Jai Rane Co-creator: Barbara Shaw

Vol 216, Issue 6: 28 March 2022. DR CR Robert George is a microbiologist and pathologist with John Hunter Hospital in Newcastle. Professor Monica Lahra is Medical Director of Microbiology, NSW Health Pathology at the Prince of Wales Hospital. They talk about the decline of invasive meningococcal and influenza during the COVID-19 pandemic, to accompany their coauthored MJA Perspective. With MJA news and online editor, Cate Swannell.

Matthew Layton and Sam Rickard present Studio 1 - Vision Australia Radio's weekly look at life from a low vision and blind point of view. This week: Glaucoma. Matthew and Sam see this episode of Studio 1 most important show on the Studio 1 calendar. Glaucoma is an eye disease that can lead to permanent irreversible sight loss. Right now 150,000 Australians are suffering from glaucoma and they don't even know it.  Today, for the third year in a row, we speak to Kirk Pengilly of INXS about the time he nearly lost his sight to glaucoma at the age of 28. In what has become a bit of a tradition/running joke, Matthew and Kirk exchange music recommendations. To give us a rundown on glaucoma - what it is, what it does and what we can do to find out if we have it - we speak to Associate Professor Dr Ashish Agar, who is a Consultant Ophthalmic Surgeon at the Prince of Wales Hospital in Sydney. We also talk to Shannon Davis, a 45 year old husband and father-of-two and, until recently, high-flying senior partner at PWC. He tells the shocking story of how he suddenly discovered he had become legally blind because of glaucoma without really realising there was anything seriously wrong with his sight. -- If you've been affected by any of the issues in this week's show - or if there's something you feel we need to talk about on future shows, please do get in touch. CALL or TEXT: 04 500 78834 EMAIL: studio1@visionaustralia.org   TWITTER: http://twitter.com/varadionetwork and  http://twitter.com/whingeingpom  -- [PHOTO CAPTION: A portrait of Kirk Pengilly, moustaches resplendent, standing in front of some sort of maritime-themed mural] – GUESTS AND RESOURCES: Glaucoma Australia - https://glaucoma.org.au/ Seven Sights in Seven Days - http://sevensights.org.au/   Matthew's music recommendations #WhiteStickFest 2021:: X Ambassadors -  Headline Set - https://youtu.be/Q9T_l1SQvpY #WhiteStickFest 2021 :: Luan Pommier - Tou Pré - https://youtu.be/cz89PdggDQw   Kirk's music recommendations Rasmus Faber feat. Renae Rain - Do My Best - https://youtu.be/iyANEb9L2QU Rasmus Faber - Two Left Feet feat. Öhrn - https://youtu.be/sur26IaI7KM Black Coffee - SUBCONSCIOUSLY (Album playlist) - https://youtube.com/playlist?list=PLrN3eFofSpllg7-9LYqXH3SiyuuHTNDHX Kirk Pengilly (INXS) Chill playlists on Spotify - https://open.spotify.com/user/cc1nb78grrtov7svdecnulj88 -- Vision Australia gratefully acknowledges the support of the Community Broadcasting Foundation for Studio 1. See omnystudio.com/listener for privacy information.

In this episode of Psych Matters, Professor Lee-Fay Low is joined by Professor Henry Brodaty, Associate Professor Lyn Phillipson and Dr Meredith Gresham to discuss how to tell someone they have dementia, the evidence for post-diagnostic treatments and support, and the resources available at https://www.forwardwithdementia.org/au/Professor Lee-Fay Low is Professor in Ageing and Health, University of Sydney. She is a registered psychologist and conducts research on rehabilitation and dementia, stigma, and interventions to improve quality of life of older people.Professor Henry Brodaty is a researcher, clinician, policy advisor and strong advocate for people with dementia and their carers.  At UNSW Sydney, he is Scientia Professor of Ageing and Mental Health, Co-Director of the Centre for Healthy Brain Ageing, and Director, Dementia Centre for Research Collaboration. He has published extensively, is a senior psychogeriatrician at Prince of Wales Hospital, Sydney. He serves on multiple committees for the NSW and Australian governments and WHO.Lyn Phillipson is an Associate Professor in Public Health at University of Wollongong. Lyn has expertise in promoting understanding and change to support the creation of dementia friendly communities, improve respite for carers of people with dementia and improve dementia help-seeking and service utilisation . Dr Meredith Gresham is an Occupational Therapist with over 35 years clinical and research experience. Her practice has focused on dementia care in residential aged care, hospitals, community, rehabilitation and palliative care settings.   Links:Forward with Dementia https://www.forwardwithdementia.org/au/Feedback:If you have a topic suggestion or would like to participate in a future episode of Psych Matters, we'd love to hear from you.Please contact us by email at: psychmatters.feedback@ranzcp.orgDisclaimer:This podcast is provided to you for information purposes only and to provide a broad public understanding of various mental health topics.  The podcast may represent the views of the author and not necessarily the views of The Royal Australian and New Zealand College of Psychiatrists ('RANZCP'). The podcast is not to be relied upon as medical advice, or as a substitute for medical advice, does not establish a doctor-patient relationship and should not be a substitute for individual clinical judgement.  By accessing The RANZCP's podcasts you also agree to the full terms and conditions of the RANZCP's Website. Expert mental health information and finding a psychiatrist in Australian or New Zealand is available on the RANZCP's Your Health In Mind Website.

"How I Do It: Costoclavicular Brachial Plexus Block," by Ranjith Kumar Sivakumar, MD, Regional Anesthesia Fellow; and Manoj Kumar Karmakar, MD, FRCA, Professor and Consultant Anesthesiologist; both of the Department of Anesthesia and Intensive Care, Chinese University of Hong Kong and Prince of Wales Hospital, Shatin, Hong Kong, China. From ASRA Pain Medicine News, November 2021. See original article at www.asra.com/asra-news for figures and references. This material is copyrighted.   

Please join Guest Host and Associate Editor Mercedes Carnethon and author Christine Albert as they discuss the article "Effect of Long-Term Marine ω-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis." Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to The Journal and its editors. We are your co-hosts, I'm Dr. Carolyn Lam, Associate Editor from the National Heart Center and Duke National University of Singapore. Dr. Greg Hundley: And I'm Dr. Greg Hundley, Associate Editor, Director of the Pauley Heart Center, VCU Health in Richmond, Virginia. Dr. Carolyn Lam: Greg, today's feature paper is such an important question clinically. It's something I've asked myself and so I cannot wait to discuss it in greater detail. It refers to the effect of long-term marine omega-3 fatty acid supplementation, and the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes. So it talks about a systematic review and meta-analysis published in this week's issue. Dr. Carolyn Lam: All right. Okay. You got to wait in suspense, as do I, and let's discuss other papers, very important papers in today's issue too. I'd like to start with a bit of a quiz. So Greg, for converting atrial fibrillation, is the anterior-lateral or anterior posterior electrode position better? What's your guess? Dr. Greg Hundley: Oh, wow, Carolyn. That's interesting. We put these pads on and we kind of just follow the directions on whatever the particular device says. Interesting question. It's a guess, Carolyn, it's a guess. Antro-lateral? Dr. Carolyn Lam: Smarty pants. Well, let's see. Frankly I didn't know the answer. It's just such an elegant question, isn't it? To answer in a study. And this is exactly what Professor Løfgren from Randers University Hospital and Denmark and colleagues did. They performed a multi-center investigator initiated open label trial, where they randomly assigned 468 patients with atrial fibrillation scheduled for elective cardioversion to anterior-lateral versus anterior-posterior electrode position. Dr. Carolyn Lam: The primary outcome was the proportion of patients in sinus rhythm after the first shock. And so drum roll. The primary outcome occurred in 54% assigned to an anterior-lateral electrode position. And in 33% assigned to an anterior-posterior electrode position, a significant risk difference of 22% in favor of the anterior-lateral electrode position. Dr. Carolyn Lam: Cheers, Greg. There were no significant differences between groups in any safety outcomes and the superiority of the anterior-lateral electrode position was statistically significant both after the initial low energy shock and after a final high energy shock. So this study really suggests a practice change in the standard approach to electrode positioning for cardioversion in favor of anterior-lateral electrode position. Dr. Greg Hundley: Very nice, Carolyn. Very nice. Well, I'm going to come at you using your heart failure expertise and ask you a quiz here in just a second. But first I want to introduce this paper from Dr. Javier Barallobre-Barreiro from King's College London. Okay, Carolyn, here's your quiz. Do you think that the extracellular matrix fibrosis contributes to LV dysfunction in heart failure patients? Dr. Carolyn Lam: Absolutely. Dr. Greg Hundley: Very nice. I think, of course, you are correct. So Carolyn, remodeling of the extracellular matrix is a hallmark of heart failure and this team's previous analysis of the secretome of mirroring cardiac fibroblast returned ADAMTS5, a disintegrin and metalloproteinase with thrombospondin motifs 5 as one of the most abundant proteases. So ADAMTS5 cleaves chondroitin sulfate proteoglycans such as Versican. The contribution of ADAMTS5 and its substrate Versican to heart failure is unknown. Dr. Carolyn Lam: Ah, so what did the authors find, Greg? Dr. Greg Hundley: Well, first Carolyn, there was a methodologic advance here. Left ventricular tissues from 86 heart failure patients and non-failing controls were analyzed by quantitative mass spectrometry, constituting the largest proteomics analysis on human heart failure today. And so what did they find? Accumulation of proteoglycan Versican was regulated by ADAMTS5, that disintegrin and metalloproteinase with thrombospondin motifs 5, and was associated with the reduction in proteins involved in intercellular communication. And Carolyn, interestingly, proteoglycan accumulation in ischemic heart failure was attenuated by beta blocker administration. Dr. Carolyn Lam: Oh, that's very interesting. Could you put that all together for us? What's the clinical implications, Greg? Dr. Greg Hundley: You bet, Carolyn. So proteoglycan secretion by cardiac fibroblast constitutes an important component of cardiac fibrosis after ischemic heart failure, just like you stated at the beginning with your quiz answer. This contributes to impaired cardiac function and besides their negative chronotropic and inotropic effects, beta blockers may modulate extracellular matrix remodeling. Dr. Carolyn Lam: Wow, nice, Greg, thank you for that. I've got another original paper and it deals with the very important topic of endothelial to mesenchymal transition. Now it has been reported that cardiac endothelial cells contribute to a substantial proportion of myofibroblast through this process called endothelial to mesenchymal transition. Lineage tracing studies have demonstrated that myofibroblasts are derived from expansion of resident fibroblasts rather than from transdifferentiation from endothelial cells. Dr. Carolyn Lam: However, it remains unknown whether endothelial cells can transdifferentiate into myofibroblast reversibly or would these endothelial to mesenchymal transition genes just transiently activated in endothelial cells during cardiac fibrosis? So these authors, corresponding authors, Dr. Sun from Shanghai Jiao Tong University School of Medicine, Dr. Lui from Price of Wales Hospital and Chinese University of Hong Kong, as well as Dr. Zhou from the University of Chinese Academy of Sciences in Shanghai and their colleagues. Dr. Carolyn Lam: What they did is they used the dual recombination technology to generate a genetic lineage tracing system for tracking endothelial to mesenchymal transition in cardiac endothelial cells and their genetic fate mapping results basically showed that although mesenchymal gene expression was activated in cardiac endothelial cells throughout the endothelial to mesenchymal transition in the developing heart, the endothelial cells do not transdifferentiate into myofibroblasts, nor do they transiently express some known mesenchymal genes during homeostasis or fibrosis in the adult heart. Resident fibroblasts that are converted to myofibroblast by activating mesenchymal gene expressions are in fact the major contributors to cardiac fibrosis. Dr. Greg Hundley: Ah, Carolyn, very interesting. So can you put this together? What are the clinical implications? Dr. Carolyn Lam: So what it really says is that it's the resident fibroblasts that are converted to myofibroblast by activating mesenchymal genes. These are the ones that represent a major therapeutic target and really unraveling these mechanisms, driving endothelial to mesenchymal transition in such a detailed way, provided new insights into therapeutic development to target cardiac fibrosis. Dr. Greg Hundley: Wow, Carolyn. You know, two really good preclinical science articles speaking to us about myocardial fibrosis. Dr. Carolyn Lam: Well, there are other papers in today's issue too. There's a Perspective piece by Dr. Christopher Lamb on “Liver Cirrhosis and Hepatocellular Carcinoma After the Fontan Operation: Reaching Clarity in the Face of Uncertainty. And this is paired with a Research Letter by Dr. Toshio Nakanishi on incidents and expected probability of liver cirrhosis and hepatocellular carcinoma after the Fontan operation. Dr. Greg Hundley: Very nice, Carolyn, and I've got an “In the News” piece from Bridget Kuehn entitled “Centering Equity in Cardiovascular Care as Michelle Albert Lays Out a Roadmap for our Profession.” Well, Carolyn, how about we learn a little more about those long term marine omega-3 fatty acid supplementations and the risk of atrial fibrillation? Dr. Christine Albert: Oh, I can't wait. Let's go, Greg. Dr. Mercedes Carnethon: Thank you so much for joining us for today's episode of Circulation on the Run. My Lame is Mercedes Carnethon, Professor and Vice Chair of Preventive Medicine at the Northwestern University Feinberg School of Medicine and Associate Editor at Circulation. And I have the great pleasure today of having a conversation with a long time friend, Dr. Christine Albert from the Department of Cardiology at the Smidt Heart Institute at Cedars-Sinai Medical Center in Los Angeles. Dr. Mercedes Carnethon: And today I've got the great pleasure of hearing directly from Christine about a wonderful original research piece that is being featured in Circulation about the effect of long term marine omega-3 fatty acid supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes. And the exciting innovation of this piece that we'll dig into is what we're learning from the systematic review and meta-analysis that Dr. Albert and her team carried out. So, thank you so much for joining us today, Christine. Dr. Christine Albert: Well, thank you, Mercedes. It's really great to be here. Dr. Mercedes Carnethon: Great. Well, I'd just like to launch with you telling us a little bit about the study, what you found, why you decided to conduct this meta-analysis and review. Dr. Christine Albert: Yeah. Great. So my first author, Dr. Baris Gencer and I decided to do this because we actually had participated in a randomized trial called the Vital Rhythm Trial, where we actually randomized people to omega-3 fatty acids and atrial fibrillation, and found a slightly elevated risk, but it wasn't significant. And at that time, a number of other articles came out saying that there really was an increased risk of atrial fibrillation. Dr. Christine Albert: So we wanted to put together the data to see what the combined data, our data, that's been published before, on this sort of long term treatment with omega-3 fatty acids and atrial fibrillation. As you may know, there have been studies that have looked at short term treatment, and specifically for atrial fibrillation, and did not find benefit. So this is why we went ahead and did this study. And what we did is we were able to find seven randomized trials that collected data on atrial fibrillation that had randomized people to omega-3 fatty acids over an average of about five years of follow up between all the different trials. And we found that when you combine all these trials together, you actually see that there is a slightly elevated risk of atrial fibrillation in the participants that were randomized to the omega-3 fatty acids. Dr. Mercedes Carnethon: Thank you so much for that summary, Christine. I think the findings themselves surprised me. This is not my primary area of work, but we hear so much about supplements and their benefits that I thought it was really telling to actually have these data coming from a large number of studies, and particularly large studies that suggest that there is a risk to benefit ratio that we need to consider. How would you recommend that clinicians weigh this evidence that you've generated today? Dr. Christine Albert: So I think that it's got to be individualized. There are benefit, as you said, of these omega-3 fatty acids. And I think it's just awareness, awareness that this potentially is a risk. If you have a patient on omega-3 fatty acids and they start to have atrial fibrillation, there could be a link. Also when you talk about it with patients, I think it's reasonable, especially with the higher doses, we can just discuss that this is a potential side effect. Does it prevent you from using it? I don't think so. I think you have to look at what is, again, as you said, the risk benefit ratio for the individual patient. And as I alluded to, we did do a dose analysis and we found that the risk was primarily seen, and it was higher, in those that were given more than a gram of omega-3 fatty acid a day. Dr. Christine Albert: However, I will say that the trials are very different when you take a meta-analysis, it's really hard to say, "What is the cause of the differences between trials?" You know, these trials that had the higher dose, the reduce it trial that used just a purified EPA was very different than the dose of the medication that was used in vital, different than the type of medication that was used in strength. And as you know, there's the whole debate about the placebo and reduce it versus strength. And so there are other differences, but one thing that is pretty consistent is that most of the point estimates are on the side of harm. So there is the thought that I think this is potentially very real and we should be considering it when we use these supplements. Dr. Mercedes Carnethon: You know, that's a really nice summary which really launches me into two subsequent questions. The first would give you the opportunity to speculate beyond the findings in your particular study, and this is one of the benefits to me of this Circ on the Run podcast, because you, of course, produced excellent science and weighed all of your findings based on what you found. But can you tell me, based on your experience, could you speculate about what you think the mechanism of elevated risk of atrial fibrillation is, particularly with those higher doses? Dr. Christine Albert: Yeah, no, it's interesting. You know, if you look at the epidemiology for this, Mercedes, it was totally inconsistent. When I postulated doing the vital rhythm trial, I actually have to be honest with you, I thought that there might be an increased risk, because when you look at some of the data of what these omega-3 fatty acids do, they increase vegal tone, they lower heart rate. They can actually slow conduction. So potentially those electrophysiologic actions might, might allow atrial fibrillation to emerge in people who are susceptible. Dr. Christine Albert: On the flip side, all of those things might be good for ventricular arrhythmias. So you see, if you look at the literature, there's benefits for…sudden death and epidemiologic studies and in some of the randomized trials, but then when you look at atrial fibrillation, at least the short terms, really didn't show a benefit. And again, that point estimate was more towards harm. Dr. Christine Albert: And then when you look at epidemiologic studies, looking at fish consumption, there's actually a lot of studies that suggest that people who eat more fish get more AFib. So it is really paradoxical. And we know as electrophysiologist that atrial arrhythmias and ventricular arrhythmias are not the same, we give drugs to prevent atrial arrhythmias that then cause ventricular arrhythmias. So it is interesting. And I think it's something that hopefully some of our translational scientists will help us to figure out. Dr. Mercedes Carnethon: All those contradictions are so challenging, but you were certainly speaking my language in describing the hypothesized mechanisms. It calls to mind, back in the day, in your early research on sudden cardiac death that I was citing as part of my dissertation work in epidemiology. So thank you for that. Dr. Christine Albert: Yeah. Dr. Mercedes Carnethon: You know, the second question that builds off of that is I thought that the figure where you display the heterogeneity by the dosage of omega-3's really underscores the argument that you were just presenting. What I was wondering is, did you happen to study heterogeneity by any other characteristics, particularly sex or age? Dr. Christine Albert: That would be fantastic to be able to do, unfortunately, because it's a summary level meta-analysis, we really can't do that. And that's one of the things that we'd love to do in collaboration with some of these authors if they would like to do that, is to really get that sort of paid participant level data, so we could do those kinds of analysis. Dr. Christine Albert: But what we did do is sort of separate out studies that had like confirmed AF, studies that had incident AF versus recurrent AF, so things where the studies were completely different, we were able to look for heterogeneity and we didn't find anything that suggested that there was heterogeneity on that basis. But there's a number of things that I would love to look at and age is definitely one of them, and also sex. And actually looking at, which would be really interesting, is to look at the omega-3 or EPA and DHA levels in these individuals. And again, I think each study has sort of tried to do it on their own and you can't because there's just not enough data. So putting all this data together would be great to have a better understanding of what's going on. Dr. Mercedes Carnethon: Oh, it sounds speaks to a number really thoughtful future directions for this work. One of the benefits of me being able to speak with you today in my role as a guest podcast host, but I was also the Associate Editor for the piece and was really excited when it came in. The discussions that we had amongst the editors about this were really very stimulating and raised a number of questions that led to you responding and making some modifications and explaining certain things. Could you tell our audience, why did you select trials over a certain size? You know, quite often we do meta-analyses in order to pull together smaller studies, but why did you choose larger studies? Dr. Christine Albert: I think it was so that, there were two criterias, one was larger and one was long term, because we felt that the smaller studies had been merged together previously and we wanted to have at least some data on atrial fibrillation. One of the problems I think that I think I want to emphasize a little bit here about research in general in cardiovascular disease is that until now, most studies hadn't really measured atrial fibrillation, and I think it's really important. And I think you can see, you can find off target effects of some of the agents that we use for cardiovascular disease on atrial fibrillation. So for instance, the Statin Trials, everybody said, "Oh, well statins might lower atrial fibrillation," but then nobody measured atrial fibrillation, so we never knew. And then people went back and tried to measure it as a side effect or something that has all kinds of biases to it. Dr. Christine Albert: So I think that what is exciting about this work is that both reduce it and strength and vital, pre-specified that they were going to look at atrial fibrillation. And so if we do that, we may actually find other agents that are beneficial, not just harm, but beneficial, like the SGLT2 inhibitors, there's lots of hypotheses. So the reason that we did pick the bigger trials was that we wanted to find trials that really kind of looked at atrial fibrillation, had enough power to look at atrial fibrillation and then over a long term, a follow up to gather enough events. Dr. Mercedes Carnethon: Again, it has been such a pleasure to hear directly from you. I really hope that our listeners today and our readers of The Journal will dig into this in the same way that we have as editors and really appreciate the thoughtfulness with which you've presented this outstanding work. So I want to thank you so much, Dr. Albert for joining us today. Dr. Christine Albert: Thank you for having me. Dr. Mercedes Carnethon: I guess I will sign off now. This is Mercedes Carnethon from the Northwestern University Feinberg School of Medicine and Associate Editor for Circulation. Disclaimer: This program is copyright of the American Heart association, 2021. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American heart Association. For more, visit ahajournals.org.

Q fever has made it to the urban fringes and is no longer just a rural health issue A structured and syndromic approach will allow GPs, especially urban GPs, to include Q fever on our list of differential diagnoses Stepwise guidance on specific diagnosis, empirical management, when to refer and when to suspect chronic Q fever and also whom and how to get vaccinated Host: Dr David Lim | Total time: 35 mins Guest: Prof Andrew Lloyd, Infectious Diseases Physician, Prince of Wales Hospital, Sydney; Academic Researcher, Kirby Institute, University of NSW Register for our fortnightly FREE WEBCASTS Every second Tuesday | 7:00pm-9:00pm AEST Click here to register for the next one See omnystudio.com/listener for privacy information.

In this week's episode, Indu Jacob, member of the WA Professional Education committee, chats to Rachelle Robinson, Senior Speech Pathologist in Head and Neck Oncology at the Prince of Wales Hospital, Sydney. Rachelle explores the role of a speech pathologist in adult tracheostomy management. Refer to Speech Pathology Australia's Learning Hub for details of Rachelle's upcoming Live Online event. Speech Pathology Australia acknowledges the Traditional Custodians of lands, seas and waters throughout Australia, and pay respect to Elders past, present and future. We recognise that the health and social and emotional wellbeing of Aboriginal and Torres Strait Islander peoples are grounded in continued connection to culture, country, language and community, and acknowledge that sovereignty was never ceded.

This week we talk about the history of North Wales Hospital, also known as Denbigh Asylum. We also share our thoughts on a horror game that we played together. This week we played Emily Wants to Play!

Today on the episode I am delighted to have Keith Donnelly on.If you ever need inspiration or a kick up the ass to do something you always dreamed of, this is the episode for you. Keith is a true inspiration and beacon of hope for those who have always dreamed of living in Australia but feel they left it too late. Keith discusses going back to University later in life to study Mental Health Nursing in Dublin and then moving his family to the other side of the world to start a new life in Sydney. But Keith didn't stop there, as well as a full-time job in the Prince of Wales Hospital, Keith has set up Keith's Closet, for Mental Health Patients. "A lot of our mental health patients have insufficient clothing so my purpose was to change that by transforming our seclusion room into a walk-in wardrobe complete with a fitting room in a very relaxed environment."What an inspiring story. Follow Keith's journey and get in touch to help volunteer @keithsclosetofficialkeith.donnelly@health.nsw.gov.au. This bonus episode is sponsored by MTM Legal, a boutique personal injury law firm located in the heart of the Sydney CBD. After nearly two decades working in a larger firm, the Founder Mary Moloney began MTM Legal in 2014 to offer the best in accident and injury legal services and advice.Contact: 02 9252 8824 , https://mtmlegal.com.au/ or instagram @mtm.legalFollow @acountydownunder on instagram for top tips when moving abroad and join our sunrise social communities all over the world.

In 2016, 340 children were adopted in Wales. Ten month old Shayla O'Brien was one of those 340 children. Like most children put up for adoption, Shayla had entered this world under difficult circumstances. Born to a drug-addicted mother, she was added to the child protection register at birth, in November 2014. She left hospital when she was five days old and she was quickly taken into care by the Vale of Glamorgan council, before being placed with a foster family, where she remained until she was placed with an adoptive family in September 2015, at the age of ten months. This adoptive family consisted of two parents, Craig and Matthew Scully-Hicks, and a previously adopted older child. Matthew assumed the majority of the caring responsibilities for Shayla, and she remained as a 'looked after child' following her placement with the family until the making of the Adoption Order. The Adoption Order was granted in May 2016 and Shayla's name was changed to Elsie. She was now officially a member of the Scully-Hicks family. This should have been the beginning of a happier life for Elsie, a life filled with love and opportunity… But it wasn't to be. Just two weeks after the official adoption had been granted, Elsie would lie dead in her bed at the University of Wales Hospital, having suffered a catalogue of catastrophic injuries at the hands of Matthew Scully-Hicks. Just what happened to baby Elise... Join us as we take a deep dive into this disturbing and tragic case. Patreon: www.patreon.com/seeingredpodcast Sponsor: www.issuu.com/podcast - use promo code red Theme Music: Composed by Holly-Jane Shears - www.soundcloud.com/DeadDogInBlackBag

In 2016, 340 children were adopted in Wales. Ten month old Shayla O'Brien was one of those 340 children. Like most children put up for adoption, Shayla had entered this world under difficult circumstances. Born to a drug-addicted mother, she was added to the child protection register at birth, in November 2014. She left hospital when she was five days old and she was quickly taken into care by the Vale of Glamorgan council, before being placed with a foster family, where she remained until she was placed with an adoptive family in September 2015, at the age of ten months. This adoptive family consisted of two parents, Craig and Matthew Scully-Hicks, and a previously adopted older child. Matthew assumed the majority of the caring responsibilities for Shayla, and she remained as a 'looked after child' following her placement with the family until the making of the Adoption Order. The Adoption Order was granted in May 2016 and Shayla's name was changed to Elsie. She was now officially a member of the Scully-Hicks family. This should have been the beginning of a happier life for Elsie, a life filled with love and opportunity… But it wasn't to be. Just two weeks after the official adoption had been granted, Elsie would lie dead in her bed at the University of Wales Hospital, having suffered a catalogue of catastrophic injuries at the hands of Matthew Scully-Hicks. Just what happened to baby Elise... Join us as we take a deep dive into this disturbing and tragic case. Patreon: www.patreon.com/seeingredpodcast Sponsor: www.issuu.com/podcast - use promo code red Theme Music: Composed by Holly-Jane Shears - www.soundcloud.com/DeadDogInBlackBag

Clinicians who treat vasculitis are familiar with uncertainty.In its many forms, and with no single sign, symptom or investigation strong enough to confirm a diagnosis, vasculitis presents an extensive list of challenges in a setting where diagnostic delay can lead to devastating consequences.In episode three of our Rheumatology Advanced Trainee series we deep dive into two types of vasculitis -giant cell arteritis (GCA) here in part 1 and ANCA-associated vasculitis next week in part 2. You'll hear Dr Tony Sammel and Dr Daman Langguth discuss what they've learned about how to diagnose the rare condition and how to best support patients through treatment decisions and relapse. They'll share tips on how to overcome some of the challenges associated with ruling out other more common conditions, making decisions around imaging and biopsy as well as discussing some of the latest evidence around treatments.With many practical tips and insights, this episode is a great listen. Dr Daman Langguth is VMO at Wesley Hospital, Brisbane, director of Immunology and chair of Partners Sullivan Nicolaides Pathology and treasurer of the Australian and New Zealand Vasculitis Society.Dr Tony Sammel is a staff specialist in rheumatology at Prince of Wales Hospital in Randwick and Sydney Eye Hospitals, where he coordinates the rheumatology vasculitis service, he has teaching appointments at the University of NSW and is Director of the Australian and New Zealand Vasculitis Society.This series is a collaboration with the Australian Rheumatology Association and the limbic. 

Clinicians who treat vasculitis are familiar with uncertainty.In its many forms, and with no single sign, symptom or investigation strong enough to confirm a diagnosis, vasculitis presents an extensive list of challenges in a setting where diagnostic delay can lead to devastating consequences.In episode three of our Rheumatology Advanced Trainee series we deep dive into two types of vasculitis -giant cell arteritis (GCA) here in part 1 and ANCA-associated vasculitis next week in part 2. You'll hear Dr Tony Sammel and Dr Daman Langguth discuss what they've learned about how to diagnose the rare condition and how to best support patients through treatment decisions and relapse. They'll share tips on how to overcome some of the challenges associated with ruling out other more common conditions, making decisions around imaging and biopsy as well as discussing some of the latests evidence around treatments.With many practical tips and insights this episode is a great listen. Dr Daman Langguth is VMO at Wesley Hospital, Brisbane, director of Immunology and chair of Partners Sullivan Nicolaides Pathology and treasurer of the Australian and New Zealand Vasculitis Society.Dr Tony Sammel is staff specialist in rheumatology at Prince of Wales Hospital in Randwick and Sydney Eye Hospitals, where he coordinates the rheumatology vasculitis service, he has teaching appointments at the University of NSW and is Director of the Australian and New Zealand Vasculitis Society.This series is a collaboration with the Australian Rheumatology Association and the limbic. 

Clinicians who treat vasculitis are familiar with uncertainty.  In its many forms, and with no single sign, symptom or investigation strong enough to confirm a diagnosis, vasculitis presents an extensive list of challenges in a setting where diagnostic delay can lead to devastating consequences. In episode three of our Rheumatology Advanced Trainee series we deep dive into two types of vasculitis -  giant cell arteritis (GCA) here in part 1 and ANCA-associated vasculitis next week in part 2. You'll hear Dr Tony Sammel and Dr Daman Langguth discuss what they've learned about how to diagnose the rare condition and how to best support patients through treatment decisions and relapse. They'll share tips on how to overcome some of the challenges associated with ruling out other more common conditions, making decisions around imaging and biopsy as well as discussing some of the latests evidence around treatments. With many practical tips and insights this episode is a great listen. Dr Daman Langguth is VMO at Wesley Hospital, Brisbane, director of Immunology and chair of Partners Sullivan Nicolaides Pathology and treasurer of the Australian and New Zealand Vasculitis Society. Dr Tony Sammel is staff specialist in rheumatology at Prince of Wales Hospital in Randwick and Sydney Eye Hospitals, where he coordinates the rheumatology vasculitis service, he has teaching appointments at the University of NSW and is Director of the Australian and New Zealand Vasculitis Society. This series is a collaboration with the Australian Rheumatology Association and the limbic. New episodes of season one will be drop every week over the next four weeks, so be sure to follow the limbic podcast in your favourite podcast app so you don't miss out. You can also visit us at the limbic to get all the latest rheumatology news delivered to your email.

On today's episode of Coogee Voice, we sit down and talk with Keith, from Keith's Closet. Keith's Closet – the brainchild of Keith Donnelly, Clinical Nurse Specialist and Community Mental Health Case Manager at Prince of Wales Hospital – has helped clothe and accessorise more than 200 vulnerable clients at the Kiloh Centre. We discuss how Keith's closest has helped hundreds of people and what you can do to support this amazing initiative.

Long COVID is a reality, but investigations rarely demonstrate significant structural damage GPs need to assess carefully with history, examination, appropriate investigation, and referral if necessary Treatment is supportive with attention given to mental health   Host: Dr David Lim | Total time: 33 mins Guest: Andrew Lloyd, Infectious Diseases Physician, Prince of Wales Hospital, Sydney; Academic Researcher, Kirby Institute, University of NSW   Register for our fortnightly FREE WEBCASTS Every second Tuesday | 7:00pm-9:00pm AEDT Click here to register for the next one See omnystudio.com/listener for privacy information.

This piece focuses on iDelirium; The International Federation of Delirium Societies on world delirium day. As well as considering this difficult condition the conversation asks what the latest research shows us and how things could improve both for patients and practitioners. For more detail check out their website here: http://www.idelirium.org/ Presented by Desiree Chappell and Monty Mythen with their guests Heidi L. Lindroth, Senior Associate Consultant Nurse Scientist, Nursing Research Division Critical Care Nurse, Gideon Caplan, Director, Geriatric Medicine, Prince of Wales Hospital, Alasdair Macclullich, Professor of Geriatric Medicine, Honorary Consultant in Geriatric Medicine, Edinburgh, Delirium Research Group, Rakesh C. Arora, Co-Founder of IDelirium, Professor and Head of Cardiac Surgery and Cardiac Critical Care at Max Rady College of Medicine - University of Manitoba, Canada.

Vol 214, Issue 7: 12 April 2021. Dr Elly Redwood is a Basic Physician Trainee at Prince of Wales Hospital and Community Health Services. Professor David Brieger is an interventional cardiologist and Professor of Cardiology at Concord Repatriation General Hospital. They talk about the importance of ambulance transport to hospital in the event of ST-elevated myocardial infarction. With MJA news and online editor, Cate Swannell.

This piece focuses on iDelirium; The International Federation of Delirium Societies on world delirium day. As well as considering this difficult condition the conversation asks what the latest research shows us and how things could improve both for patients and practitioners. For more detail check out their website here: http://www.idelirium.org/ Presented by Desiree Chappell and Monty Mythen with their guests Heidi L. Lindroth, Senior Associate Consultant Nurse Scientist, Nursing Research Division Critical Care Nurse, Gideon Caplan, Director, Geriatric Medicine, Prince of Wales Hospital, Alasdair Macclullich, Professor of Geriatric Medicine, Honorary Consultant in Geriatric Medicine, Edinburgh, Delirium Research Group, Rakesh C. Arora, Co-Founder of IDelirium, Professor and Head of Cardiac Surgery and Cardiac Critical Care at Max Rady College of Medicine - University of Manitoba, Canada.

This wide ranging talk asks where and how we should focus on the needs of postoperative care patients. "Brain care has an impact way beyond the acute surgical episode"; how do we minimise the risks of a poor outcome when it comes to postoperative care? "Advanced recovery from anaesthesia and surgery" is a talk originally given at the 8th Australian and New Zealand Symposium of Perioperative Medicine Special Interest Group: “Updates in Perioperative Medicine 360” which took place between November 7th-9th 2019. Presented by Professor Jacqueline Close, Principal Research Fellow, NeuRA Conjoint Professor, UNSW Consultant Geriatrician, Prince of Wales Hospital.

"It also must start and end in primary care" This piece is a fascinating in-depth conversation moving through various medical perspectives on perioperative medicine from Australia and New Zealand. A real highlight of the festival. How has perioperative medicine evolved over the years around the world? What's the status of Perioperative Care as a specialty? How does one specialise in this area, in terms of education? Discussing the development of the International Board:- "We decided perioperative education should not only be available for developed countries". We hear that TopMedTalk engaging with the African Perioperative Research Group (APORG) has helped move the cause of perioperative care forward, both in Africa and elsewhere. The conversation further evolves: Once educated how do we demonstrate the value of perioperative practice? How do we launch projects that will really make a difference? Where, from a research perspective, do the more fruitful areas of investigation present themselves? Would a minimum data set help? Moving to clinical trials we hear how research is being conducted, both the challenges and the sources of success. "Perioperative medicine is a team sport" - how do we use the interdisciplinary aspect of what we do to enhance our educational options? Regular listeners to TopMedTalk may recall the series we did about the Perioperative Special Interest Group (SIG) - if you want more details of http://www.anzca.edu.au/fellows/special-interest-groups/perioperative-medicine The ANZCA Clinical Trials Network can be found at http://www.anzca.edu.au/ctn Also, The International Board of Perioperative Medicine is here: https://www.internationalboardpom.org/ Further, make sure you check out https://www.periopmedicine.org.uk/ for more information on the perioperative medicine short course we discuss. And Perioperative Medicine for The Junior Clinician is available here: https://www.amazon.co.uk/Perioperative-Medicine-Junior-Clinician-Symons/dp/1118779169 Presented by Desiree Chappell alongside co-host Ross Kerridge, Anaesthetist from Newcastle in Australia - sometimes called the 'Father of Perioperative Medicine'. Guests are Jill Van Acker, Staff Specialist Anaesthetist and Clinical Lead Perioperative Services, Canberra Hospital, and Chair of the ANZ Perioperative Special Interest Group; Vanessa Beavis, President, Australian & New Zealand College of Anaesthetists, & until recently Director of Perioperative Services, Auckland District Health Board; Prof. Jackie Close Orthogeriatrician at the Prince of Wales Hospital in Sydney and Clinical Director of the Falls, Balance and Injury Research Centre at Neuroscience Research Australia; Prof. Dave Story, Head of the ANZCA Clinical Trials Network, and Chair of the Anaesthesia, Perioperative and Pain Medicine Unit within the University of Melbourne Medical School. Joel Symons, Anaesthetist at the Alfred Hospital in Melbourne and Senior Lecturer at Monash University, Leader in the development of Educational Programs based at Monash University and member of International Board of Perioperative Medicine.

On the show today we chat with Dr Ryan Dashwood, a fellow of the Australasian College for Emergency Medicine. who talks about the importance the emergency department can have in the care of Aboriginal and Torres Strait Islander patients.   Bio: Dr Dashwood is a fellow of the Australasian College for Emergency Medicine. Dr Dashwood joined UWS School of Medicine, as a Lecturer of Aboriginal and Torres Strait Islander Health and is also involved in medical student support.   Dr Dashwood started his career in Medicine with a Bachelor of Science, Double Major in Biotechnology and Medical Microbiology and Immunology at the University of New South Wales. From 2001 until 2005 he worked as a Trainee Scientist at the Children's Hospital Westmead and the Prince of Wales Hospital, Randwick in Cytogentics moving into a the Hospital Scientist role from 2005 until 2007. In 2005 he completed a Graduate Certificate of Health Science (Indigenous Community Health) and then in 2006 attended the University of Sydney Medical Program, graduating in 2009 with a Bachelor of Medicine and Bachelor of Surgery.

On the show today we chat with Dr Ryan Dashwood, a fellow of the Australasian College for Emergency Medicine. who talks about the importance the emergency department can have in the care of Aboriginal and Torres Strait Islander patients.Bio:Dr Dashwood is a fellow of the Australasian College for Emergency Medicine. Dr Dashwood joined UWS School of Medicine, as a Lecturer of Aboriginal and Torres Strait Islander Health and is also involved in medical student support.Dr Dashwood started his career in Medicine with a Bachelor of Science, Double Major in Biotechnology and Medical Microbiology and Immunology at the University of New South Wales. From 2001 until 2005 he worked as a Trainee Scientist at the Children’s Hospital Westmead and the Prince of Wales Hospital, Randwick in Cytogentics moving into a the Hospital Scientist role from 2005 until 2007. In 2005 he completed a Graduate Certificate of Health Science (Indigenous Community Health) and then in 2006 attended the University of Sydney Medical Program, graduating in 2009 with a Bachelor of Medicine and Bachelor of Surgery.

In this Episode: Fatigue appears to be the most common issue affecting Australians recovering from COVID-19 How to assess? What are the red flags? How to differentiate between psychogenic vs post-viral fatigue? What can be done about it? Host: Dr David Lim, GP Guest: Prof Andrew Lloyd, Infectious Diseases Physician, Head of the Viral Immunology Systems Program (VISP), Kirby Institute, the National Centre for Cancer Survivorship (NCCS) and the UNSW Fatigue Clinic, University of NSW; Prince of Wales Hospital; Justice Health Total time: 24 mins   FREE Webcast! Tuesday, 8 September 2020 7:00pm-9:15pm AEST Register Now! See omnystudio.com/listener for privacy information.

TB clinical presentation is complex. This is because TB may involve any tissue or organ, the severity of symptoms range from none to overwhelming, the tempo of the illness ranges from indolent to rapid, symptoms/ findings may be local or systematic, the presentation varies in immunocompromised and diagnostic tests such as TST or IGRA cannot provide an official diagnosis alone. Due to the complexity of TB, clinician's may find difficulty in recognising. TB presentation. Dr Hazel Goldberg provides an insight into understanding TB clinical presentation. Dr Hazel Goldberg is a Respiratory Consultant who runs the Tuberculosis clinic at the Prince of Wales Hospital in Randwick, Sydney. She oversees services which include diagnosing and managing active TB, screening for latent TB infection (LTBI) among health care workers, those exposed to TB, migrants and the immune suppressed and treating LTBI, organising radiology surveillance as well as BCG vaccination service. 

This piece is a fascinating in-depth conversation moving through various medical perspectives on perioperative medicine from Australia and New Zealand. A real highlight of the festival. How has perioperative medicine evolved over the years around the world? What's the status of Perioperative Care as a specialty? How does one specialise in this area, in terms of education?  Discussing the development of the International Board:- "We decided perioperative education should not only be available for developed countries".  We hear that TopMedTalk engaging with the African Perioperative Research Group (APORG) has helped move the cause of perioperative care forward, both in Africa and elsewhere.  The conversation further evolves:-  Once educated how do we demonstrate the value of perioperative practice? How do we launch projects that will really make a difference? Where, from a research perspective, do the more fruitful areas of investigation present themselves? Would a minimum data set help?  Moving to clinical trials we hear how research is being conducted, both the challenges and the sources of success.  "Perioperative medicine is a team sport" - how do we use the interdisciplinary aspect of what we do to enhance our educational options? Regular listeners to TopMedTalk may recall the series we did about the Perioperative Special Interest Group (SIG) - if you want more details of http://www.anzca.edu.au/fellows/special-interest-groups/perioperative-medicine The ANZCA Clinical Trials Network can be found at http://www.anzca.edu.au/ctn Also, The International Board of Perioperative Medicine is here: https://www.internationalboardpom.org/ Further, make sure you check out https://www.periopmedicine.org.uk/ for more information on the perioperative medicine short course we discuss. Presented by Desiree Chappell alongside co-host Ross Kerridge, Anaesthetist from Newcastle in Australia - sometimes called the 'Father of Perioperative Medicine'.  Guests are Jill Van Acker, Staff Specialist Anaesthetist and Clinical Lead Perioperative Services, Canberra Hospital, and Chair of the ANZ Perioperative Special Interest Group;  Vanessa Beavis, President, Australian & New Zealand College of Anaesthetists, & until recently Director of Perioperative Services, Auckland District Health Board;  Prof. Jackie Close Orthogeriatrician at the Prince of Wales Hospital in Sydney and Clinical Director of the Falls, Balance and Injury Research Centre at Neuroscience Research Australia; Prof. Dave Story, Head of the ANZCA Clinical Trials Network, and Chair of the Anaesthesia, Perioperative and Pain Medicine Unit within the University of Melbourne Medical School. Joel Symons, Anaesthetist at the Alfred Hospital in Melbourne and Senior Lecturer at Monash University, Leader in the development of Educational Programs based at Monash University and member of International Board of Perioperative Medicine.

This wide ranging talk asks where and how we should focus on the needs of postoperative care patients. "Brain care has an impact way beyond the acute surgical episode"; how do we minimise the risks of a poor outcome when it comes to postoperative care? "Advanced recovery from anaesthesia and surgery" is a talk originally given at the 8th Australian and New Zealand Symposium of Perioperative Medicine Special Interest Group: “Updates in Perioperative Medicine 360” which took place between November 7th-9th 2019. Presented by Professor Jacqueline Close, Principal Research Fellow, NeuRA Conjoint Professor, UNSW Consultant Geriatrician, Prince of Wales Hospital.

Welcome to COVID Chronicles with Jenny Rudolph, a just-in-time podcast checking in with friends and colleagues from the front lines of healthcare, the home front, and other unique perspectives on learning and connecting in the time of coronavirus. Albert Chan (twitter.com/gaseousXchange) is an anesthesiologist at Prince of Wales Hospital in Hong Kong, where they've been applying lessons learned during the SARS outbreak of 2003 to help prepare for COVID-19. Albert's infographic on safe airway management in patients with confirmed/suspected coronavirus has gone worldwide, helping clinicians on the internet to build better infection control processes and keep themselves safe. The success of this just in time learning, first published on the Life in the Fast Lane blog, has now been written up in Anaesthesia. Listen along as we learn how to use simulation as a tool to make providers feel safe when they have to take care of COVID-19 postive patients, building collective competence and confidence among the staff.

Paracetamol (acetaminophen) overdose is increasing, and with a variety of formulations available, the management can quickly become complex. Dr Angela Chiew is a Clinical Toxicologist and Emergency Physician from Sydney's Prince of Wales Hospital, and the New South Wales Poison's Information Centre.  She joins Todd to discuss the new Australasian Guidelines, of which she is a leading author.   The guidelines can be found here

On May 12, 2015, 90 year old William MacDonald died in the secure wing of Prince of Wales Hospital in Sydney, Australia. At the time of his death he was the longest serving prisoner in a New South Wales Prison, however beyond aficionados of true crime, very few know his name or of the heinous crimes he committed that gave him the name “The Sydney Mutilator”. Yet the strange way in which he was caught, should give him a greater place in infamy. See acast.com/privacy for privacy and opt-out information.

When Louisa Hope walked into Sydney’s Lindt Cafe 5 years ago she didn't expect her life would change forever. Louisa is one of the Sydney Siege survivors. She and her mother were held at gunpoint and trapped for 17 hours before the gunman executed cafe manager Tori Johnston on his knees in front of her. Another hostage, Katrina Dawson was killed moments later in gunfire when police stormed the cafe. Louisa joins Mia Freedman to talk through what happened that day and how she feels five years on. Towards the end of the siege, Louisa was shot in the foot and went to The Prince of Wales Hospital where she spent 3 months as a patient. She was so moved by the care and compassion she received there, she decided to create the Louisa Hope Fund for Nurses as part of the Prince of Wales Hospital Foundation. To Donate to the Prince of Wales Hospital Foundation, Louisa Hope Fund for Nurses please visit www.powhf.org.au Click here to subscribe to No Filter. CREDITS: Host: Mia Freedman  With thanks to Louisa Hope Producer:  Bridget Northeast GET IN TOUCH: Call the PodPhone on 02 8999 9386. Email the show at podcast@mamamia.com.au No Filter is a podcast by Mamamia. Find more shows here See omnystudio.com/listener for privacy information.

When Louisa Hope walked into Sydney’s Lindt Cafe 5 years ago she didn't expect her life would change forever. Louisa is one of the Sydney Siege survivors. She and her mother were held at gunpoint and trapped for 17 hours before the gunman executed cafe manager Tori Johnston on his knees in front of her. Another hostage, Katrina Dawson was killed moments later in gunfire when police stormed the cafe. Louisa joins Mia Freedman to talk through what happened that day and how she feels five years on. Towards the end of the siege, Louisa was shot in the foot and went to The Prince of Wales Hospital where she spent 3 months as a patient. She was so moved by the care and compassion she received there, she decided to create the Louisa Hope Fund for Nurses as part of the Prince of Wales Hospital Foundation. To Donate to the Prince of Wales Hospital Foundation, Louisa Hope Fund for Nurses please visit www.powhf.org.au Click here to subscribe to No Filter. CREDITS: Host: Mia Freedman  With thanks to Louisa Hope Producer:  Bridget Northeast GET IN TOUCH: Call the PodPhone on 02 8999 9386. Email the show at podcast@mamamia.com.au No Filter is a podcast by Mamamia. Find more shows here See omnystudio.com/listener for privacy information.

When Louisa Hope walked into Sydney’s Lindt Cafe 5 years ago she didn't expect her life would change forever. Louisa is one of the Sydney Siege survivors. She and her mother were held at gunpoint and trapped for 17 hours before the gunman executed cafe manager Tori Johnston on his knees in front of her. Another hostage, Katrina Dawson was killed moments later in gunfire when police stormed the cafe. Louisa joins Mia Freedman to talk through what happened that day and how she feels five years on. Towards the end of the siege, Louisa was shot in the foot and went to The Prince of Wales Hospital where she spent 3 months as a patient. She was so moved by the care and compassion she received there, she decided to create the Louisa Hope Fund for Nurses as part of the Prince of Wales Hospital Foundation. To Donate to the Prince of Wales Hospital Foundation, Louisa Hope Fund for Nurses please visit www.powhf.org.au Click here to subscribe to No Filter. CREDITS: Host: Mia Freedman  With thanks to Louisa Hope Producer:  Bridget Northeast GET IN TOUCH: Call the PodPhone on 02 8999 9386. Email the show at podcast@mamamia.com.au No Filter is a podcast by Mamamia. Find more shows here See omnystudio.com/listener for privacy information.

Friday Drive welcomed David Murphy, an emergency department doctor and Grahame Conlon, a former patient of the Prince of Wales Hospital who came down to the studio to talk to us about the Prince of Wales Hospital Foundation. This year they are supporting the Emergency Department and the incredibly important work that they do. David [...]Read More... from POWH Foundation Christmas Stories

Friday Drive welcomed David Murphy, an emergency department doctor and Grahame Conlon, a former patient of the Prince of Wales Hospital who came down to the studio to talk to us about the Prince of Wales Hospital Foundation. This year they are supporting the Emergency Department and the incredibly important work that they do. David […]

Vol 211, Issue 11: 2 December 2019. Dr Angela Chiew is an emergency physician and toxicologist at the Prince of Wales Hospital and the NSW Poisons Information Centre. She talks about recent recommended changes in practice for the management of paracetamol poisonings. With MJA news and online editor Cate Swannell.

If we look at the evidence, is there a case for "vascular geriatrics"? Co-managed care in vascular surgery could be a way forward, this talk builds the case for change. Readmission rates in this group are dissapointing, how do we reasonably tackle this issue? How do we balance questions regarding appropriateness and need for surgery in this area? What about the priorities of the patient, do they align with our aims? Is it possible there are geriatiricans who are already doing co-management with vascular surgeons? Is it fair to say that vascular surgeons need help the most? The talk is followed by a short case study regarding the model of care at Prince of Wales Hospital and Community Health Services, Department of Geriatrics. Presented by Vasi Naganathan, Academic and Consultant Geriatrician at University of Sydney, Concord Repatriation Hospital, New South Wales, Australia; followed by a second brief 'case study' from Christina Norris, Prince of Wales Hospital and Community Health Services, Department of Geriatrics. -- Brought to you by the Perioperative Medicine Special Interest Group (SIG) in association with the Australian and New Zealand Society for Geriatric Medicine and the Internal Medicine Society of Australia and New Zealand at the 7th annual Australasian Symposium of Perioperative Medicine. The Perioperative Medicine Special Interest Group (SIG) has three aims; improve patient safety and outcomes, share knowledge and collaborate with specialty groups, develop the specialty of perioperative medicine with various craft groups. For more information follow this link here: http://www.anzca.edu.au/fellows/special-interest-groups/perioperative-medicine

Welcome back to Audible bleeding today we have our second of hopefully many collaborative VSITE review series.  Today we’re going to talk about Thoracic outlet syndrome and our content was put together by Dr. Nedal Katib, who is a senior vascular surgery fellow at the Prince of Wales Hospital in Sydney, Australia. No need to take notes!  Full TOS outline found here. Support Audible Bleeding here!

This JCO Podcast provides observations and commentary on the JCO article “Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment for Stage IIIA-N2 EGFR-Mutant NSCLC (EMERGING-CTONG 1103): A Randomized Phase II Study” by Zhong et al. My name is Tony Mok, and I am a Professor of Clinical Oncology at the Chinese University of Hong Kong in the Prince of Wales Hospital in Hong Kong. My oncologic specialty is Medical Oncology.   With the advent of molecular targeted therapy, patients harboring driver oncogenes may now survive longer and better than before, and EGFR mutation is the prime example of such achievement. However, evidence for “cure” of patients with metastatic EGFR mutation positive lung cancer remains scanty. In contrast, It may be more reasonable to first attempt cure of patients with earlier stage disease using molecular targeted therapy. CTONG 1103, published in this issue of Journal of Clinical Oncology, is the first randomized study comparing neoadjuvant erlotinib with chemotherapy for patients with stage IIIA EGFR mutation positive lung cancer.   CTONG 1103, the report that accompanies this podcast, is not an easy study to conduct. Between December 2011 and December 2017, investigators from 17 centers across China managed to screen 386 patients with stage IIIA non-small cell lung cancer (NSCLC) and identified only 72 (which is about 19%) eligible EGFR mutation positive patients. They were randomized to receive either erlotinib 150mg daily for 42 days or two cycles of chemotherapy using gemcitabine and cisplatin as neo-adjuvant therapy. After neoadjuvant therapy, 73% of the erlotinib arm, and 63% of the chemotherapy arm, received curative surgery, including two patients in erlotinib arm who received pneumonectomy. The primary endpoint of this study is tumor response rate, which is 54.1% for erlotinib and 34.3% for chemotherapy. However, the odds ratio of 2.26 for tumor response rate was not statistically significant. Two other important and impactful endpoints include major pathological response and progression free survival (PFS). Major pathological response is defined as less than 10% residual viable tumor cell and it occurred only in 10.7% of patients who received erlotinib and none with the chemotherapy. But on the other hand, PFS was significantly better with erlotinib arm, reporting median of 21.5 month comparing with 11.4 months with chemotherapy arm.   In reference to the primary endpoint of tumor response rate, we should conclude that CTONG 1103 is a negative study. Zhong et al has reasonably estimated the sample size based on a presumptive response rate of 70% in the erlotinib arm and 36% in the chemotherapy arm.  The reported response rate at 54.1% with erlotinib in this study has significantly fallen short of the expected rate of 70%, which was actually the widely accepted response rate in patients with stage IV disease. The authors selected to offer 42 days of neo-adjuvant erlotinib in order to match the two cycles of neo-adjuvant chemotherapy. While there is no biologic reason to explain the low response rate in earlier stage disease, the shorter duration of treatment may contribute to the relatively lower response rate. The other important outcome is the major pathological response of 10.7% with neo-adjuvant erlotinib, which is supposed to be a surrogate for overall survival. Hellman et al were among the first groups to suggest the predictive power of major pathological response for neo-adjuvant chemotherapy for patients with early stage lung cancer. The lower than expected major pathological response may be considered a surrogate indicator for overall survival but it is more important to wait for the mature survival outcomes.   A negative study can still be impactful. This study has established the feasibility of neo-adjuvant EGFR TKI for patients with potentially resectable EGFR mutation positive lung cancer. The first single arm phase II study on pre-operative gefitinib published in 2009 in the Journal of Clinical Oncology enrolled 36 patients but only 6 harbored the activating EGFR mutations. Tumor response was observed in 4 patients and all were positive for the mutations. Another single arm study published in 2018 in the journal The Oncologist enrolled 19 patients with EGFR mutation positive stage IIIA NSCLC and treated with neoadjuvant erlotinib for 56 days. Tumor response rate was 42.1% and resection rate was 68.4%. Only 5 of the 14 patients (35.7%) with surgical resection had documented pathologic downstaging from N2 to N0/N1 disease. The median PFS and OS was 11.2 and 51.6 months respectively. CTONG 1103 is the first and only randomized comparative study that confirmed the feasibility and efficacy of neo-adjuvant EGFR TKI. Tumor response rate is higher than chemotherapy by 20% although not statistically significant, but toxicity profile is better, which is an established fact from multiple phase III studies on advanced stage disease. The resection rates were similar between the two arms but it was unclear how many of the enrolled patients had unresectable disease prior to neo-adjuvant therapy. Key objectives of neo-adjuvant therapy are to down-stage tumor/nodal disease and to improve resectability. This randomized study may potentially document if erlotinib is more capable of converting unresectable stage IIIA disease to being resectable, however, this data is not currently available.   The authors of the current study have also reported improvement in progression free survival, but we cannot conclude that the improvement is solely due to the neo-adjuvant therapy. As per study protocol, patients from neo-adjuvant EGFR TKI arm did receive 12 months of erlotinib as adjuvant therapy while the chemotherapy arm received only 2 more cycles of similar treatment. Considering the duration of therapy, the adjuvant erlotinib may in fact  contribute more to prolongation of progression free survival than the neo-adjuvant therapy. In 2017 in the journal Lancet Oncology, the same group of investigators have reported a randomized phase III study comparing adjuvant gefitinib with chemotherapy and the median disease free survival was 28.7 months and 18.0 months, respectively. All patients enrolled in this study had resectable lung cancer with over 60% of patients having N2 disease, and the authors had concluded on the potential survival advantage of adjuvant EGFR TKI. Thus, the improvement in progression free survival should be explained by both neo-adjuvant and adjuvant erlotinib.   In summary, CTONG 1103 is a negative study but it has significant impact on management of stage IIIA EGFR mutation positive lung cancer. With high screening failure rate at 80%, it took the authors 6 years to enroll 72 patients. This study will remain the only randomized study on this patient group for a long time as similar  large scale phase III trials of this strategy will be unlikely. Clinicians are obligated to share and explain CTONG 1103 to patient with stage IIIA EGFR mutation positive lung cancer. For patients with resectable disease at presentation, the benefit of neo-adjuvant EGFR TKI may be debatable. But for patients with un-resectable stage IIIA disease, neo-adjuvant EGFR TKI may potentially downstage the disease status and facilitate resection.     This concludes this JCO podcast. Thank you for listening.

Season 3, Episode 4 welcomes Oscar Lederman. What was initially meant to be one of our monthly Audio Abstracts, the information presented to us by Oscar was too good to pass up! Having recently completed his PhD at the University of NSW, Oscars thesis gives a great insight on how we can improve the physical and mental health of young people in the early stages of psychosis, namely through exercise and lifestyle interventions. As an Exercise Physiologist at the Prince of Wales Hospital in Sydney, Oscar gives a unique approach on how we can use exercise as a means to treat chronic health conditions, with his research focusing heavily on physical activity for mental illness. Along with his current commitments to work and research, Oscar also has previous experience in Physiotherapy and spent over four years as a Senior Surf Instructor with Let’s Go Surfing in Bondi Beach, Australia. You can follow Oscar on Twitter @OscarLederman or check out some of his research at https://www.researchgate.net/profile/Oscar_Lederman. Hope you enjoy the episode! For any further questions or information, please contact me at: Email: iandunican@sleep4performance.com.au Twitter @sleep4perform www.sleep4performance.com.au  You can also listen to S4P Radio on You Tube and Spotify.

Stroke recovery is a marathon; it's not a sprint. Regaining cognitive skills, physical skills, sensory skills, and more takes time and work. During that time, life can be really hard and unpleasant for many folks. The may or may not be able to work. Relationships get turned upside down, and after a while you just want it to go away. Surely, with all the advances in medicine, there must be something…some fancy technology or machine…some magic technique that will fix these problems, right? That leads folks to look for and explore alternatives. It also means that many survivors start pursuing things that don't work. Hyperbaric oxygen therapy appears to be one of those therapies. In Hyperbaric Oxygen Therapy, the patient spends time in a pressure chamber where the air pressure is 2-3X normal and breathes pure oxygen. They get roughly 8-12X as much oxygen as in their normal lives. This, supposedly, should grow new blood vessels in the brain and revive the dead neurons that were killed by the stroke, or drive new growth through neuroplasticity. I saw a number of people asking about it in Facebook groups and twitter feeds, so I began talking with folks to learn more. Strokecast regular, neurologist Dr Nirav Shah, introduced me to one of the world's leading authorities on Hyperbaric Oxygen therapy, Dr. Mike Bennett in Australia. This week I talk with Dr. Bennett about the theory and the research around hyperbaric medicine. We answer the key questions about it -- is it safe, and does it work. The short version is that it is mostly safe, but there is no reliable research demonstrating that it works. The main risk is to the patient's wallet. Bio Professor Bennett is the Academic Head of the Department of Anaesthesia, a Senior Staff Specialist in diving and hyperbaric medicine at Prince of Wales Hospital and Conjoint Professor in the faculty of Medicine, University of New South Wales in Sydney, Australia. He graduated from the University of New South Wales in 1979 and spent his early post-graduate training at the Prince Henry/Prince of Wales Hospitals before undertaking training in Anaesthesia in the UK. He returned to Sydney in 1990 as a retrieval specialist on the Lifesaver Helicopter and here developed an interest in both diving and hyperbaric medicine. He also has a strong interest in clinical epidemiology and is an experienced clinician and researcher. In 2002 he was the recipient of the Behnke Award for outstanding scientific achievement from the Undersea and Hyperbaric Medical Society. Since 2004 he has been highly involved in the teaching of Evidence-based Medicine within the Medical faculty at UNSW and in 2005 was appointed co-director of the Quality Medical Practice Program there. He is the author of over 150 peer-reviewed publications including 15 Cochrane reviews of the evidence in Diving and Hyperbaric Medicine. Prof. Bennett was the convenor of the Australia and New Zealand Hyperbaric Medicine Group Introductory Course in Diving and Hyperbaric Medicine from its inception in 1999.to 2014. He is an executive member of the Australia and New Zealand College of Anaesthetists (ANZCA) special interest group in diving and hyperbaric medicine, chief examiner for the ANZCA Certificate in diving and hyperbaric medicine and Chair of the ANZCA Scholar Role Subcommittee. He is a past Vice-President of the UHMS and currently the Past President of SPUMS. Hack of the Week -- Rocker Knife Last week, I talked about cutting meat at a restaurant -- don't. This week, let's talk about doing the same thing at home where you may not have a kitchen staff. Sure, at home you can just pick up a hunk of meat with your hands. But sometimes you still want to slice it for some reason. I use a Verti-Grip knife. It's designed for folks with use of one hand. I hold it in my fist, rock it against the meat, and it cuts right through. It doesn't require you to brace what you're cutting with a fork. For a $14 gadget, it works really well. Links Dr. Michael Bennet https://powcs.med.unsw.edu.au/people/professor-michael-bennett Hyperbaric Oxygen Therapy on MedLink http://www.medlink.com/article/hyperbaric_oxygenation_for_the_treatment_of_stroke Hyperbaric Oxygen Therapy for Acute Ischemic Stroke on AHA Journals https://www.ahajournals.org/doi/10.1161/STROKEAHA.115.008296 HBO Evidence http://hboevidence.unsw.wikispaces.net/Stroke Medical News Today -- Hyperbaric https://www.medicalnewstoday.com/search?q=hyperbaric&p=1 DMI Verti-Grip Curved Cutting Kitchen and Dinner Knife https://www.amazon.com/Verti-Grip-Individuals-Strength-Dishwasher-Stainless/dp/B00NZ0ZKES/ref=sr_1_7_a_it Bill on Pure Mind Magic https://victoriamavis.podbean.com/e/60-pmm-changing-your-brain-changing-your-body-wiht-bill-monroe/   Pure Mind Magic A few months back, German podcaster, magician, and mindset expert Victoria Mavis joined me to talk about the intersection between public speaking and magic on my other podcast, 2-Minute Talk Tips. You can find that interview at 2-MinuteTalkTips.com/magic. During December, I had the pleasure of appearing on her show, Pure Mind Magic. We talked about speaking, sure, but much of the conversation was about my stroke story and the power of mindset in recovery. You can listen to it here or subscribe for free to Pure Mind Magic in your favorite podcast app   Where do we go from here? Have you tried Hyperbaric Oxygen Therapy? Let us know in the comments at http://strokecast.com/hyperbaric Pick up a Verti-Grip knife if you need to cut thing one-handed. Share this episode with someone in your circle who is interested in alternative therapies with the link http://strokecast.com/hyperbaric Don't get best…get better     Strokecast is the stroke podcast where a Gen X stroke survivor explores rehab, recovery, the frontiers of neuroscience and one-handed banana peeling by helping stroke survivors, caregivers, medical providers and stroke industry affiliates connect and share their stories.

How much do you know about Tourette Syndrome? Could you explain to your child what it is, and how to be accepting of another child's difference? Professor Perminder Sachdev is the Clinical Director of the Neuropsychiatric Institute at the Prince of Wales Hospital in Sydney. He explains how Tourette Syndrome affects children at school, and what parents can do to support them.

This week, we continue our suburb deep dive series on the Sydney Property Insider Podcast via our Suburb Spotlight! Today, we’re focussing on the lovely area of Clovelly.   We discuss the history of the suburb, the demographics, upcoming development work, as well as the day-to-day specifics like local cafes, schools and transport   HERE’S WHAT YOU’LL LEARN FROM TODAY’S EPISODE:   The history of Clovelly; The original residents of the suburb; The estates in the area during the 19th century; Entry level prices; Price data over past few years; How tightly held property in the suburb is; Transport links to the CBD; Public transport on the way for the area; Proximity to Prince of Wales Hospital; School zoning; Necessities in proximity; An underwater trail; And Dog friendly parks nearby   LINKS OR ARTICLES WE MENTIONED:   Bondi to Coogee Walk Underwater Nature Trail edu.au School Finder   SPEAKERS IN TODAY’S EPISODE Michelle May - Sydney Buyers Agent Marcus Roberts - Mortgage Broker   ASK US ANYTHING!   Have a money question you want us to answer? ask@sydneypropertyinsider.com.au   FOLLOW US: Facebook   ENJOY THE SHOW? Don’t miss an episode, subscribe viaiTunes. If you like it, please leave a review! Or, find us on the podcast app of your choice, such as Spotify  

Above: Prof. Chung (Left), me and Mr. Li in Zhuhai, China in March 2018 While I was in China (March 2018) conducting research and recording episodes for the new show, I had the great pleasure to meet Professor Sydney Chung (钟尚志 / Zhong Shangzhi), who is a recognized expert and pioneer in medicine, particularly in the area of endoscopy. Prof. Chung was the President of The Chinese University Hong Kong School of Medicine and the youngest President in the school’s history.  Prof. Chung studied medicine at the Royal College of Surgeons in Ireland and worked at Prince of Wales Hospital in Hong Kong upon graduation.  At the age of 50, he experienced his version of the "midlife crisis" and decided to go to Papua New Guinea, the Land of the Unexpected to work as a doctor for three years, often under extreme circumstances with limited medical and Human Resources.  What I also found out is that Prof. Chung was a key contributor (and known to be one of the heroes) during SARS in Southern China between 2002-2003.  This is a very short interview, only about 15-minute long. Prof. Chung had a busy schedule but I couldn't resist the opportunity to meet him in person. To learn more about Professor Chung，I hope you check out his book, the Kindest Cut in both Chinese and English.  Visit Feisworld.com for more stories from unsung heroes and self-made artists.  --- Send in a voice message: https://anchor.fm/feisworld/message Support this podcast: https://anchor.fm/feisworld/support

Julian Gold, professor in the department of neuroscience and trauma, Queen Mary, University of London, and senior staff specialist, Albion Centre, Prince of Wales Hospital, Sydney, discusses his paper which investigates whether or not HIV protects against developing MS.Read the paper, for free: HIV and lower risk of multiple sclerosis: beginning to unravel a mystery using a record-linked database study http://goo.gl/j0G3SR

David Bihari is an Intensivist from Prince of Wales Hospital in Sydney. He is particularly interested and passionate about nutrition in the critically ill, and has been involved in research in this area for many years.

Sumesh Arora, an intensivist from Prince of Wales Hospital in Sydney talks about what dysbarism is, and the role of hyperbaric oxygen therapy. See the slides on Intensive Care Network.